BUDGET IMPACT ANALYSIS OF TEPOTINIB IN ENGLAND FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING

被引：0
|
作者：
McLean, T. [1 ]
Alexopoulos, S. [1 ]
Hook, E. [2 ]
Batterson, R. [2 ]
Vioix, H. [3 ]
机构：
[1] Merck Serono Ltd, Feltham, England
[2] Delta Hat Ltd, Nottingham, England
[3] Merck Healthcare KGaA, Darmstadt, Germany
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE447
引用
收藏
页码：S143 / S143
页数：1
相关论文
共 50 条
  • [1] MOMENT REGISTRY (MET NON SMALL CELL CANCER REGISTRY) FOR ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING
    Thomas, M.
    Christopoulos, P.
    Iams, W. T.
    Mazieres, J.
    Cortot, A. B.
    Peled, N.
    Minuti, G.
    Smit, E. F.
    Ahrens, S.
    Berghoff, K.
    Eggleton, S. P.
    Fries, F.
    Liu, P.
    Mahmoudpour, S. H.
    Menzel, C.
    O'Brate, A.
    Stroh, C.
    Oksen, D.
    VALUE IN HEALTH, 2023, 26 (12) : S527 - S527
  • [2] US health utility in advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 (METex14) skipping mutations treated with tepotinib
    Paik, Paul K.
    Yang, Mo
    Knowles, Emma
    Hatswell, Anthony
    Vioix, Helene
    Liu, Frank Xiaoqing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [3] Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
    Reinmuth, N.
    Popat, S.
    Paz-Ares, L.
    Knowles, E.
    Hatswell, A.
    McLean, T.
    Adrian, S.
    Gaumond, B.
    Vioix, H.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S985 - S986
  • [4] Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
    Scherz, A.
    Felip, E.
    Garassino, M.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E.
    Mazieres, J.
    Cortot, A.
    Raskin, J.
    Viteri, S.
    Iams, W. Thomas
    Kim, H. R.
    Yang, J. -J.
    Stroh, C.
    Otto, G.
    Bruns, R.
    Paik, P.
    SWISS MEDICAL WEEKLY, 2021, 151 : 36 - 36
  • [5] Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping
    Yang, J. C-H.
    Ahn, M-J.
    Sakai, H.
    Morise, M.
    Kato, T.
    Chen, Y-M.
    Han, J-Y.
    Yang, J-J.
    Zhao, J.
    Huang, J.
    Berghoff, K.
    Bruns, R.
    Otto, G.
    Le, X.
    Paik, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S41 - S42
  • [6] Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14)
    Furqan, Muhammad
    Karanth, Siddharth
    Goyal, Ravi K.
    Shih, Yu-Hsuan
    Cai, Beilei
    Rombi, Julien
    Davis, Keith L.
    Caro, Nydia
    Saliba, Teddy Rassem
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF TEPOTINIB WITH CAPMATINIB IN PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) WITH MET EXON 14 (METEX14) SKIPPING
    Paik, P.
    Pfeiffer, B.
    Vioix, H.
    Postma, M. J.
    VALUE IN HEALTH, 2022, 25 (12) : S28 - S28
  • [8] Tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC): Interim analysis of VISION Cohorts A and C
    Griesinger, Frank
    Thomas, Michael
    Reinmuth, Niels
    Wermke, Martin
    Overbeck, Tobias
    Alt, Juergen
    Henschke, Sven
    Wehler, Thomas
    Ochsenreither, Sebastian
    Garassino, Marina Chiara
    Felip, Enriqueta
    Sakai, Hiroshi
    Bruns, Rolf
    Otto, Gordon
    Johne, Andreas
    Paik, Paul K.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 154 - 154
  • [9] Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States
    Stargardter, Matthew
    McBride, Ali
    Tosh, Jon
    Sachdev, Rameet
    Yang, Mo
    Ambavane, Apoorva
    Mittal, Madhav
    Vioix, Helene
    Liu, Frank Xiaoqing
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 816 - 827
  • [10] Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping.
    Kato, Terufumi
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Sakai, Hiroshi
    Morise, Masahiro
    Chen, Yuh-Min
    Han, Ji-Youn
    Yang, Jin-Ji
    Zhao, Jun
    Huang, Jason
    Berghoff, Karin
    Bruns, Rolf
    Vioix, Helene
    Otto, Gordon
    Le, Xiuning
    Paik, Paul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345